Form 4: EyePoint Pharmaceuticals Director Increases Stake with Open Market Purchases
SEC Form 4
Director Karen L. Zaderej increased her holdings in EyePoint Pharmaceuticals through open market purchases on May 14 and 15, 2025.
Summary
- Karen L. Zaderej, a director of EyePoint Pharmaceuticals, acquired 5,000 shares of common stock on May 14, 2025, at a weighted average price of $5.42.
- She then acquired another 5,000 shares on May 15, 2025, at a weighted average price of $5.47.
- Following these transactions, Zaderej directly owns 26,500 shares of EyePoint Pharmaceuticals common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director's purchase of shares often signals confidence, but the scale of the purchase is not large enough to be overwhelmingly positive.
Positives
- A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This type of insider transaction is common and closely watched by investors for signals about management's view of the company's value and prospects. It is a routine part of the market.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Director purchased 5,000 shares at a weighted average price of $5.42. |
| 05/15/2025 | Director purchased 5,000 shares at a weighted average price of $5.47. |
| 05/15/2025 | Date of the signature of the Attorney-in-Fact. |
Keywords
EyePoint Pharmaceuticals, EYPT, Zaderej, Director, Stock Purchase, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.